PGK1 and benign prostatic hyperplasia: Our previous work on PGK1 function at nerve terminals was motivated in part by the discovery that this enzyme is activated as an off-target effect by the FDA approved treatment for benign prostate hyperplasia (BSH), Terazosin (TZ) and that TZ was shown in retrospective analysis to significantly lower the risk of Parkinson’s Disease (PD)42,43.